沈中阳教授创建器官移植学科——器官移植中心亚洲大规模器官移植中心之一OrganTransplantSurgeryinitiatedbyProfessorShenZhongyangOrganTransplantCenteroneofthelargeOrganTransplantCenterinAsia天津市第一中心医院器官移植中心成立于1998年，在国家863计划器官移植领域专家沈中阳教授的带领下成为我国获卫生部批准可以同时开展肝脏、肾脏、心脏、胰腺、小肠、肺脏、眼角膜以及胰岛细胞移植的中心，设有肝移植科、肾移植科、心脏移植科、小儿肝移植科、肝胆外科、细胞移植科、移植监护室、血透中心、移植实验室等学科，是目前亚洲大规模器官移植中心之一，也是被ClinicalTransplants收录的中国大陆器官移植中心。移植手术数量与质量在全国连续多年保持领先，完成肝移植手术近万例，约占国内总例数的三分之一，肝移植术后生存率达先进水平。TheOrganTransplantCenterofTianjinFirstCentralHospitalwasestablishedin1998.Undertheleader-shipofProfessorShenZhongyang,theexpertinorgantransplantfieldof"National863Program",ithasbeenauthorized.bytheMinistryofHealth,PRC(MOH)astheOrganTransplantcenterinChinawhichcanperformtransplantationsofliver,kidney,heart,pancreas,smallintestine,lung,corneaandcellsandnowamultidisciplinaryresourcesstructureoflivertranspl-antationDept.,renaltransplantationDept.,hearttransplantationDept.,pediatriclivertransplantationDept.,hepatobiliarysurgeryDept.,cellstransplantationDept.,TransplantICU,hemodialysiscenterandtransplantlaboratoryetc.SofarOrganTransplantCenterhassuccessfullyperformednearlytenthousandcasesoflivertransplantationsandkepttheleadinglevelinsurgerynumbers,survivalrateandpost-surgerylifequalitiesinChina.IthasbeenoneofthelargeOrganTransplantCenterinAsiaandalsotheChinamainlandtransplantcenterwhichwasrecordedby"ClinicalTransplants".1994年完成我国第一例长期存活的肝移植手术，保持国内肝移植患者长期生存纪录达11年之久。研究创立了乙肝病毒相关性肝病肝移植后乙肝再感染的综合防治体系(目前全国使用的标准方案)，使移植后乙肝再感染率从80%以上下降到5%以下，肝移植患者的平均生存期从2-3年延至长期生存，突破我国肝脏移植瓶颈。与此同时，协助全国22个省市80家医疗单位成功开展首例肝移植，为推动我国肝脏移植技术在临床常规开展做出了开拓性贡献。2014年沈中阳教授获"全国十佳科技工作者"，其带领的团队获"全国杰出专业技术人才先进集体奖"。ThefirstlivertransplantofOOTCwasperformedin1994andkeptarecordofdomesticlong-termsurvivalafterlivertransplantationfor11years.ThecentertakesaleadinmanyaspectsoforgantransplantfieldinmainlandChina.Meanwhile,thestudiesatOOTCcreatedacomprehensivesystemforpreventingHBVre-infectionafterlivertransplantationwhichwasthetreatmentforHBV-associatedliverdisease(currentlynationalguideline).ThissystemreducestherateofHBVre-infectionafterlivertransplantationfromover80%tobelow5%,thusthesurvivaltimeofhepatitisBpatientsafterlivertransplantationhasbeenconsiderablyextendedfrom2-3yearstolong-termsurvivingandtheirlifequalityhasbeengreatlyimproved.Inaddition,thecenterhassuccessivelyhelped80medicalunitsin22districtsinChinawithlivertransplantations.ItmadegreatcontributionstothepopularizationandthedevelopmentoflivertransplantationinChina.In2014Prof.ShenZhongyangwonthe"NationalTopTenScienceandTechnologyWorkers"andOOTCwonthe"NationalOutstandingProfessionalandTechnicalPersonnelAdvancedCollectiveAward".